September 22, 2026 10:06 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
IIT Bombay protests erupt after student’s death; authorities meet students over 18 demands | Mithu Mukherjee, the vivacious 70s heroine with a flirtatious charm, passes away | Zelenskyy speaks to Trump, announces New York meeting amid Russia-Ukraine conflict | Italy PM Meloni announces big school plan: Burqa, hijab ban and cap on foreign students | Arvind Kejriwal, family ‘missing’ from Delhi voter list, claims Aam Aadmi Party | ‘No UPI above ₹2,000?’ Ghaziabad traders put up ‘cash only’ hoardings | Trump signs Russia sanctions bill: India faces fresh 100% tariff threat over Moscow oil | Caught using ChatGPT for exam answers, IIT Bombay student dies by suicide; students protest | Congress' Nandigram candidate arrested after Mamata's support amid TMC symbol row; Bengal bypoll gets chaotic | Gurugram murder shocker: Groom-to-be leaves sisters at Delhi restaurant to meet ex-colleague, found dead days later
Coronavirus Vaccine

Adar Poonawalla thanks PM Modi for decisive 'policy changes and swift financial aid' amid vaccine shortage

| @indiablooms | Apr 21, 2021, at 07:18 am

Mumbai/IBNS: Serum Institute of India (SII) CEO Adar Poonawalla has lauded the Centre's policy change in vaccination, bringing all above 18 under the mass drive and extending financial support to the vaccine manufacturers.

SII which is manufacturing Covishied, developed by Oxford University and Swedish drug giant AstraZeneca, in India has been given Rs 3,000 crore as 100 per cent advance till July, reported NDTV citing senior sources in the Finance Ministry.

A similar advance of Rs 1,500 crore has been given to Hyderabad-based Bharat Biotech, the producer of indegenous Covaxin, the report added.

"This will ensure that the two companies get necessary funding to continue and scale up production," the sources said, the report added.

Earlier, Adar Poonawalla had appealed to the Centre for funds to scale up manufacturing amid high demand of the vaccine within and outside India.

Both Bharat Biotech and SII were facing shortage of funds "to scale up production, purchase raw materials, pay staff, and make and distribute enough doses of the vaccines", stated the report.

Poonawall, on Tuesday, tweeted in appreciation of the Centre's move.

The states can now buy coronavirus vaccine doses directly from manufacturers in the "liberalised and accelerated Phase 3 strategy of COVID-19 vaccination".

.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.